(Press-News.org) The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. In a paper that will appear in the July 23/28 issue of JAMA – a theme issue on HIV/AIDS receiving early online release to coincide with the International AIDS Conference – Massachusetts General Hospital (MGH) investigators report that daily injections of tesamorelin significantly reduced fat in the liver without affecting glucose metabolism.
"Tesamorelin's ability to reduce liver fat in conjunction with the reduction of abdominal fat may be clinically important for patients with HIV infection who have fatty liver disease along with increased abdominal fat," says Steven Grinspoon, MD, of the MGH Neuroendocrine Unit and Program in Nutrition Metabolism, the study's senior author. "While some patients with nonalcoholic fatty liver disease have a benign course, others may develop a more serious condition involving liver inflammation, cellular damage and fibrosis, which can progress to cirrhosis and end-stage liver disease or to liver cancer."
Between 30 and 40 percent of HIV-infected patients develop nonalcoholic fatty liver disease (NAFLD), often but not always in conjunction with lipodystrophy, the abnormal abdominal fat accumulation that develops in 20 to 30 percent of patients receiving antiretroviral drugs. Tesamorelin stimulates the body's release of growth hormone, which is reduced in HIV lipodystrophy, and several studies by Grinspoon's team and others led to the 2010 approval of the drug to treat the lipodystrophy.
In designing the current study, the MGH team originally planned to further investigate tesamorelin's effects on abdominal fat with a secondary focus on fat in the liver and muscle, and on markers of inflammation and cardiovascular risk. But since several studies suggested a significant incidence of NAFLD in HIV-infected patients, the study's goals were broadened to focus on tesamorelin's ability to reduce fatty deposits in the liver as well as abdominal fat in general.
The study enrolled 48 adult patients who were receiving antiretroviral treatment for HIV and had developed excessive abdominal fat deposits. Participants were first randomized to receive daily injections of either tesamorelin or a placebo. In addition, since growth hormone treatment can lead to increased blood sugar levels and reduced insulin sensitivity, half of those in each group also had a procedure that analyzes insulin secretion and resistance at the study's outset and at assessment sessions conducted at three months and at the end of the six-month study. The assessments also included comprehensive measures of factors related to HIV infection, lipid and glucose metabolism, along with analysis of abdominal fat by CT scan and of liver fat by MR spectroscopy.
At the end of the study period, participants receiving tesamorelin had a significant, modestly sized decrease in liver fat along with the expected reduction in overall abdominal fat. Those receiving placebo treatment had increases in both measures. Although tesamorelin treatment did appear to have reduced insulin sensitivity and raised blood sugar levels at the three-month assessment, by six months both measures had returned to levels observed at the study's outset, implying that the drug's impact on glucose metabolism was only temporary.
"Tesamorelin's neutral long-term effects on insulin sensitivity and glucose are important, since HIV patients with abdominal fat accumulation may have underlying insulin resistance; so it's important to know that won't be worsened by this treatment," says Grinspoon, a professor of Medicine at Harvard Medical School. "Since we know that liver fat is associated with inflammation in the liver, reducing it may result in less inflammation. Indeed levels of AST, a marker of liver inflammation, were reduced in response to tesamorelin in our study.
"Now we need to investigate the effects of tesamorelin in patients with the severe form of liver inflammation called nonalcoholic steatohepatitis, which can cause significant damage to liver cells, and examine whether reduced liver fat has other metabolic benefits," he adds. "Tesamorelin also may be an effective treatment for non-HIV-infected patients with NAFLD, and that needs to be studied as well."
INFORMATION:
Takara Stanley, MD, of the MGH Neuroendocrine Unit and Program in Nutrition Metabolism is lead author of the JAMA report. Additional co-authors are Meghan Feldpausch, APRN-BC, and Jinhee Oh, MGH Neuroendocrine Unit and Program in Nutrition Metabolism; Karen Branch, RN, MGH Clinical Research Unit; Hang Lee, PhD, MGH Biostatistics; and Martin Torriani, MD, MGH Radiology. The study was funded by National Institutes of Health grants K23DK089910, R01DK063639, M01-RR01066 and 1 UL1 RR02575801. Grinspoon's previous studies of tesamorelin were supported by Theratechnologies, the Montreal-based company that markets the drug under the brand name Egrifta.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $785 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.
Drug that reduces abdominal fat in HIV patients also may reduce fat in liver
Daily treatment with tesamorelin for six months lowered liver fat modestly but significantly
2014-07-19
ELSE PRESS RELEASES FROM THIS DATE:
Study examines rate of HIV diagnosis in US
2014-07-19
The annual HIV diagnosis rate in the U.S. decreased more than 30 percent from 2002-2011, with declines observed in several key populations, although increases were found among certain age groups of men who have sex with men, especially young men, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. The issue is being released early to coincide with the International AIDS Conference.
"There has been increasing emphasis on care and treatment for persons with human immunodeficiency virus (HIV) in the United States during the past decade, including ...
Combination treatment for Hep C associated with favorable response among patients with HIV
2014-07-19
HIV-infected patients also infected with hepatitis C virus (HCV) who received a combination of the medications sofosbuvir plus ribavirin had high rates of sustained HCV virologic response 12 weeks after cessation of therapy, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. The issue is being released early to coincide with the International AIDS Conference.
Up to 7 million persons worldwide are infected with both human immunodeficiency virus (HIV) and hepatitis C virus. Treatment of this coinfection has been limited due to the need to ...
Offering option of initial HIV care at home increases use of antiretroviral therapy
2014-07-19
Among adults in the African country of Malawi offered HIV self-testing, optional home initiation of care compared with standard HIV care resulted in a significant increase in the proportion of adults initiating antiretroviral therapy, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. The issue is being released early to coincide with the International AIDS Conference.
In 2012, an estimated 35 million individuals were infected with the human immunodeficiency virus (HIV) worldwide. Antiretroviral therapy (ART) substantially reduces the risk ...
Study examines effect on pregnancy of receiving antiretroviral therapy for preventing HIV
2014-07-19
Among heterosexual African couples in which the male was HIV positive and the female was not, receipt of antiretroviral pre-exposure preventive (PrEP) therapy did not result in significant differences in pregnancy incidence, birth outcomes, and infant growth compared to females who received placebo, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. The authors note that these findings do not provide a definitive conclusion regarding the safety of PrEP therapy prior to pregnancy. The issue is being released early to coincide with the International ...
Growth hormone analog may reduce risk of fatty liver disease in HIV-infected patients
2014-07-19
In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. Patients infected with HIV demonstrate a high prevalence of nonalcoholic fatty liver disease, estimated at 30 percent to 40 percent. The issue is being released early to coincide with the International AIDS Conference.
In human immunodeficiency virus (HIV) infection, abdominal fat accumulation ...
Offering option of initial HIV care at home increases use of ART
2014-07-19
LSTM Researchers found that offering adults in Malawi optional home initiation of care following HIV self-testing resulted in a significant increase in the proportion of adults initiating antiretroviral therapy (ART) compared with standard HIV care.
The results are part of a study that was funded by the Wellcome Trust and published in the July 23/30 issue of JAMA, which is HIV/AIDS themed and released early to coincide with the International AIDS Conference taking place in Melbourne, Australia next week.
In 2012 it was estimated that 35 million people worldwide were living ...
Hepatitis C cured in co-infected HIV patients
2014-07-19
A multicenter team of researchers report that in a phase III clinical trial, a combination drug therapy cures chronic hepatitis C in the majority of patients co-infected with both HIV and hepatitis C.
"In many settings, hepatitis C is now a leading cause of death among HIV co-infected patients," says Mark Sulkowski, M.D., medical director of the Johns Hopkins Infectious Disease Center for Viral Hepatitis and professor of medicine at the Johns Hopkins University School of Medicine. Approximately one-third of HIV patients in the United States have hepatitis C, with an estimated ...
Feinstein Institute researchers identify brain network
2014-07-19
Manhassett, NY – Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation.
Parkinson's disease is the second most common neurodegenerative disease in the US. Those who suffer from Parkinson's disease most often experience tremors, slowness of movement (bradykinesia), rigidity, and impaired balance and coordination. Patients may have difficulty walking, ...
Performance improvement program helps doctors better manage depression, reports journal of psychiatric practice
2014-07-18
A performance improvement initiative for physicians can significantly increase their use of evidence-based practices in screening for and treating depression, in the July Journal of Psychiatric Practice. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Led by Dr Michael E. Thase of the University of Pennsylvania Medical School, the researchers evaluated a performance improvement continuing medical education (PI CME) program to increase physicians' use of practices that have been shown to improve diagnosis and care for depression. ...
NASA sees powerful thunderstorms in Tropical Storm Matmo
2014-07-18
Strong thunderstorms reaching toward the top of the troposphere circled Tropical Storm Matmo's center and appeared in a band of thunderstorms on the storm's southwestern quadrant. Infrared imagery from NASA's Aqua satellite showed very cold temperatures that indicated the high cloud tops in the powerful storms.
Tropical cyclones consist of hundreds of thunderstorms. When NASA's Aqua satellite flew over Tropical Storm Matmo on July 17 at 16:59 UTC (12:59 p.m. EDT) on July 17, the Atmospheric Infrared Sounder (AIRS) instrument obtained infrared data on the tropical cyclone. ...
LAST 30 PRESS RELEASES:
Global supply chains benefit most from who you know
While searching for the world’s oldest ice, scientists find sediment sneaking under the Antarctic ice sheet
Contrasting risk profiles for suicide attempt and suicide
Future-focused conservation index identifies reptiles as highest conservation priority
Ideological polarization and the spread of biased or fake news on Facebook are on the rise, according to a study by the UPF
New study reveals how tiny but powerful gatekeepers guard the nucleus
Discovery of a brown dwarf orbiting a red dwarf through the synergy of ground- and space-based observatories
CPA journal wins prestigious award at high-quality development conference
Disruptive investments can build a cleaner aviation industry
Wearable optical device distinguishes blood flow signals from the brain and scalp
USC-Caltech study moves novel tool to measure brain blood flow closer to the clinic
Changes in colorectal cancer screening modalities among insured individuals
Seaweed makes for eco-friendly tissue scaffolds and reduces animal testing
New study: AI chatbots systematically violate mental health ethics standards
Smoking both cannabis and tobacco may alter brain’s ‘bliss molecule,’ study finds
The rise of longevity clinics: Promise, risk, and the future of aging
Decoding the T-cell burst: Signature genes that predict T-cell expansion in cancer immunotherapy
Biomarker can help predict preeclampsia risk in women with sickle cell disease
AI models can now be customized with far less data and computing power
Twenty-five centers join Bronchiectasis and NTM Care Center Network
Botox-like substance brings relief to Ukrainian war amputees
People with dark personality traits use touch to manipulate their partners
It’s not just diet: where a child lives also raises type 2 diabetes risk
Predicting physical activity change after a cardiovascular diagnosis
Algorithmic outreach leads to information inequality
Szeged researchers accelerate personalized medicine with AI-powered 3D cell analysis
Offline interactions predict voting patterns better than online networks
Hanyang University researchers develop novel facet guided metal plating strategy, improving stability anode-free metal batteries
When cells run a red light: Double trouble for old models in cell division
Epigenetic reprogramming safely modifies multiple genes in T Cells simultaneously for CAR-T therapies
[Press-News.org] Drug that reduces abdominal fat in HIV patients also may reduce fat in liverDaily treatment with tesamorelin for six months lowered liver fat modestly but significantly